tbuckley/cabot-search huggingface dataset:
Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non–Small-Cell Lung Cancer: A Competing Risks Analysis
Authors: Takashi Eguchi, Sarina Bains, Ming-Ching Lee, Kay See Tan, Boris Hristov, Daniel H. Buitrago, Manjit S. Bains, Robert J. Downey, James Huang, James M. Isbell, Bernard J. Park, Valerie W. Rusch, David R. Jones, Prasad S. Adusumilli
Journal: Journal of Clinical Oncology (2016)

Purpose To perform competing risks analysis and determine short- and long-term cancer- and noncancer-specific mortality and morbidity in patients who had undergone resection for stage I non-small-cell lung cancer (NSCLC). Patients and Methods Of 5,371 consecutive patients who had undergone curative-intent resection of primary lung cancer at our institution (2000 to 2011), 2,186 with pathologic stage I NSCLC were included in the analysis. All preoperative clinical variables known to affect outcomes were included in the analysis, specifically, Charlson comorbidity index, predicted postoperative (ppo) diffusing capacity of the lung for carbon monoxide, and ppo forced expiratory volume in 1 second. Cause-specific mortality analysis was performed with competing risks analysis. Results Of 2,186 patients, 1,532 (70.1%) were ≥ 65 years of age, including 638 (29.2%) ≥ 75 years of age. In patients < 65, 65 to 74, and ≥ 75 years of age, 5-year lung cancer-specific cumulative incidence of death (CID) was 7.5%, 10.7%, and 13.2%, respectively (overall, 10.4%); noncancer-specific CID was 1.8%, 4.9%, and 9.0%, respectively (overall, 5.3%). In patients ≥ 65 years of age, for up to 2.5 years after resection, noncancer-specific CID was higher than lung cancer-specific CID; the higher noncancer-specific, early-phase mortality was enhanced in patients ≥ 75 years of age than in those 65 to 74 years of age. Multivariable analysis showed that low ppo diffusing capacity of lung for carbon monoxide was an independent predictor of severe morbidity ( P < .001), 1-year mortality ( P < .001), and noncancer-specific mortality ( P < .001), whereas low ppo forced expiratory volume in 1 second was an independent predictor of lung cancer-specific mortality ( P = .002). Conclusion In patients who undergo curative-intent resection of stage I NSCLC, noncancer-specific mortality is a significant competing event, with an increasing impact as patient age increases.
Thiotepa Containing Regimen As Conditioning Chemotherapy for Lymphoma Involving Central Nervous System Compared with BuCyE (Busulfan, Cyclophosphamide and Etoposide)
Authors: Yi Rang Kim, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Changhoon Yoo, Jeong-eun Kim, Jae-Cheol Jo, Jooryung Huh, Jeong Hoon Kim, Sang-wook Lee, Cheolwon Suh
Journal: Blood (2014)
The Role of Inhibitor of Apoptosis Proteins Family Expression In Acute Myeloid Leukemia Patients
Authors: Agnieszka Pluta, Agata Wrzesien-Kus, Barbara Cebula-Obrzut, Konrad Stepka, Anna Wolska, Olga Grzybowska-Izydorczyk, Magdalena Czemerska, Piotr Smolewski, Tadeusz Robak, Agnieszka Wierzbowska
Journal: Blood (2010)
TCT-289 Nicorandil as Hyperemic Agent to Evaluate Fractional Flow Reserve
Authors: Nobukiyo Tanaka, Hiroki Ishihara, Takuya Maeda, Masanori Teramura, Yuya Takahashi, Kei Ichihashi, Kazuhiro Dan, Tomohiko Teramoto
Journal: Journal of the American College of Cardiology (2015)
Donor T-Cells Specific for Lineage-Restricted Maturation Antigens Not Recognizing Immature Progenitor Cells May Lead to Hematologic Remission but Molecular Persistence of Chronic Myeloid Leukemia (CML).
Authors: Peter A. von dem Borne, Simone A.P. van Luxemburg-Heijs, Roel Willemze, J.H. Frederik Falkenburg
Journal: Blood (2004)
TCT-184 Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Patients with ACS vs. non-ACS: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Abhishek Sharma, Samin K. Sharma, Aakash Garg, Ajay Vallakati, Jonathan D. Marmur, Debabrata Mukherjee, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2015)
Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.
Authors: Alessandra Ferrajoli, Michael J. Keating, William G. Wierda, Susan M. O’Brien, Swaminathan Padmanabhan, Myron S. Czuczman, Asher A. Chanan-Khan
Journal: Blood (2007)
Expression of Human Enhancer of Invasion 10 (HEI10) in Human Myeloid Leukemias and Downregulation during Differentiation of Hematopoietic Stem Cells.
Authors: Naohito Fujishima, Makoto Hirokawa, Masumi Fujishima, Yoshikazu Ichikawa, Takahiro Horiuchi, Ikuo Miura, Ken-ichi Sawada
Journal: Blood (2004)
TCT-57 A Cost Analysis of Bleed Complications from Two Stroke Prevention Strategies in Non-valvular Atrial Fibrillation: Left Atrial Appendage Closure versus Warfarin
Authors: Matthew J. Price, Stacey Amorosi, Shannon Armstrong, Meghan Gavaghan, Douglas Gibson, Miguel Valderrabano, Vivek Reddy
Journal: Journal of the American College of Cardiology (2015)
Trends in Dietary Supplement Use Among US Adults From 1999-2012
Authors: Elizabeth D. Kantor, Colin D. Rehm, Mengmeng Du, Emily White, Edward L. Giovannucci
Journal: JAMA (2016)

<h3>Importance</h3> Dietary supplements are commonly used by US adults; yet, little is known about recent trends in supplement use. <h3>Objective</h3> To report trends in dietary supplement use among US adults. <h3>Design, Setting, and Participants</h3> Serial cross-sectional study using nationally representative data from the National Health and Nutrition Examination Survey (NHANES) collected between 1999 and 2012. Participants include noninstitutionalized adults residing in the United States, surveyed over 7 continuous 2-year cycles (sample size per cycle, 4863 to 6213). <h3>Exposures</h3> Calendar time, as represented by NHANES cycle. <h3>Main Outcomes and Measures</h3> In an in-home interview, participants were queried on use of supplements in the preceding 30 days to estimate the prevalence of use within each NHANES cycle, and trends were evaluated across cycles. Outcomes included use of any supplements; use of multivitamins/multiminerals (MVMM; defined as a product containing ≥10 vitamins and/or minerals); and use of individual vitamins, minerals, and nonvitamin, nonmineral supplements. Data were analyzed overall and by population subgroup (including age, sex, race/ethnicity, and educational status), and were weighted to be nationally representative. <h3>Results</h3> A total of 37 958 adults were included in the study (weighted mean age, 46.4 years; women, 52.0% ), with an overall response rate of 74%. Overall, the use of supplements remained stable between 1999 and 2012, with 52% of US adults reporting use of any supplements in 2011-2012 (<i>P</i>for trend = .19). This trend varied by population subgroup. Use of MVMM decreased, with 37% reporting use of MVMM in 1999-2000 and 31% reporting use in 2011-2012 (difference, −5.7% [95% CI, −8.6% to −2.7%],<i>P</i>for trend &lt; .001). Vitamin D supplementation from sources other than MVMM increased from 5.1% to 19% (difference, 14% [95% CI, 12% to 17%],<i>P</i>for trend &lt; .001) and use of fish oil supplements increased from 1.3% to 12% (difference, 11% [95% CI, 9.1% to 12%],<i>P</i>for trend &lt; .001) over the study period, whereas use of a number of other supplements decreased. <h3>Conclusions and Relevance</h3> Among adults in the United States, overall use of dietary supplements remained stable from 1999-2012, use of MVMM decreased, and trends in use of individual supplements varied and were heterogeneous by population subgroups.
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML
Authors: Marina Konopleva, Donna E. Hogge, David A. Rizzieri, Thomas P. Cirrito, Steven M. Kornblau, Gautam Borthakur, Carol Bivins, Guillermo Garcia-Manero, Tapan M. Kadia, Farhad Ravandi, Michael Andreeff, Jorge E. Cortes, Kenneth Hoberman, Michael Szarek, Eric Rowinsky, Ivan Bergstein, Hagop M. Kantarjian, Arthur E. Frankel
Journal: Blood (2012)
Peripheral Blood Stem Cell Mobilization In Hiv Positive Patients with Lymphoma Candidates to Autologous Transplantation: Predictive Factors Analysis for Failure or Suboptimal Stem Cell Collection
Authors: Alessandro Re, Pascual Balsalobre, Mariagrazia Michieli, Jose M. Ribera, Bernardino Allione, Camillo Almici, Pierino Ferremi, Mario Mazzucato, Chiara Cattaneo, Salvatore Casari, Michele Spina, Cristina Skert, Jose L. Diez-Martin, Umberto Tirelli, Giuseppe Rossi
Journal: Blood (2010)
Prognostic Role of PET-FDG Before Autologous Stem Cell Transplantation in Advanced Hodgkin's Lymphoma.
Authors: Alessandro Pulsoni, Elena Cavalieri, Saveria Capria, Fabio Torelli, Giorgia Annechini, Federico De Angelis, Angela Matturro, Livia Santini, Giovanna Meloni, Robin Foà
Journal: Blood (2009)
Activation of and dependence on ataxia telangiectasia mutated kinase in PTEN-deficient tumor cells.
Authors: Nuala McCabe, Steven M. Walker, Nicolas Goffard, Katarina Wikstrom, Caroline Greenan, Estelle McLean, Fionnuala A McDyer, Karen E Keating, Iain James, Timothy Harrison, Paul B Mullan, D. Paul Harkin, Clark Chen, Richard D. Kennedy
Journal: Journal of Clinical Oncology (2012)

10553 Background: Loss of PTEN function has been widely reported to cause up-regulation of the PI3K/AKT signalling pathway resulting in increased cell growth, proliferation and survival. More recently it has been reported that PTEN null cells demonstrate genomic instability and have increased production of reactive oxygen species (ROS) and oxidative stress induced DNA damage. Ataxia Telangiectasia Mutated (ATM) is the primary response kinase, which responds to stalled DNA replication and DNA double strand breaks due to oxidative DNA damage. Methods: A metagene representing ATM activation was generated from cell line data and used to perform hierarchical clustering analysis of public DNA microarray profiling datasets of breast cancer, ovarian cancer and glioblastoma with known PTEN IHC/mutation status. Furthermore, we ask if ATM activation may be therapeutically exploited in PTEN null tumours using ATM specific siRNA and compounds in 2 PTEN isogenic cell line model systems. Results: We show that PTEN null cells have elevated levels of ROS, DNA damage and have endogenous activation of ATM, an enzyme important in responding to DNA damage resulting from oxidative stress. We hypothesised that PTEN deficient tumours may rely on ATM enzyme for survival. To investigate this we generated a 189-gene list representing ATM activation and used this to perform hierarchical clustering analysis of a breast cancer DNA microarray dataset. This list was able to significantly cluster tumours with known loss of PTEN expression (p=0.004). Furthermore, this gene list was able to segregate PTEN null/mutant tumours from PTEN wild-type tumours in 2 independent datasets of glioblastoma and ovarian cancer (p=0.015 and p=0.012). In addition, we found that inhibition of ATM using the selective inhibitor KU-55933 caused DNA damage, cell cycle arrest and apoptosis specifically in PTEN deficient cells when compared to PTEN wild-type cells. Conclusions: These observations suggest that ATM may represent a therapeutic target in PTEN deficient tumours and furthermore ATM activation may be the basis of a biomarker of PTEN status in human cancers.
P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather
Authors: S. Pol, S. Lucier, H. Fontaine, C. Dorival, V. Petrov-Sanchez, M. Bourlière, J. Capeau, P. Carrieri, D. Larrey, C. Larsen, P. Marcellin, J.-M. Pawlotsky, J.-C. Trinchet, F. Zoulim, P. Cacoub, V. De Ledinghen, J. Dubuisson, P. Mathurin, F. Negro, G.-P. Pageaux, Y. Yazdanpanah, L. Wittkop, J.-P. Zarski, F. Carrat
Journal: Journal of Hepatology (2015)
An Official American Thoracic Society Research Statement: Implementation Science in Pulmonary, Critical Care, and Sleep Medicine
Authors: Curtis H. Weiss, Jerry A. Krishnan, David H. Au, Bruce G. Bender, Shannon S. Carson, Adithya Cattamanchi, Michelle M. Cloutier, Colin R. Cooke, Karen Erickson, Maureen George, Joe K. Gerald, Lynn B. Gerald, Christopher H. Goss, Michael K. Gould, Robert Hyzy, Jeremy M. Kahn, Brian S. Mittman, Erika M. Mosesón, Richard A. Mularski, Sairam Parthasarathy, Sanjay R. Patel, Cynthia S. Rand, Nancy S. Redeker, Theodore F. Reiss, Kristin A. Riekert, Gordon D. Rubenfeld, Judith A. Tate, Kevin C. Wilson, Carey C. Thomson
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Many advances in health care fail to reach patients. Implementation science is the study of novel approaches to mitigate this evidence-to-practice gap.The American Thoracic Society (ATS) created a multidisciplinary ad hoc committee to develop a research statement on implementation science in pulmonary, critical care, and sleep medicine. The committee used an iterative consensus process to define implementation science and review the use of conceptual frameworks to guide implementation science for the pulmonary, critical care, and sleep community and to explore how professional medical societies such as the ATS can promote implementation science.The committee defined implementation science as the study of the mechanisms by which effective health care interventions are either adopted or not adopted in clinical and community settings. The committee also distinguished implementation science from the act of implementation. Ideally, implementation science should include early and continuous stakeholder involvement and the use of conceptual frameworks (i.e., models to systematize the conduct of studies and standardize the communication of findings). Multiple conceptual frameworks are available, and we suggest the selection of one or more frameworks on the basis of the specific research question and setting. Professional medical societies such as the ATS can have an important role in promoting implementation science. Recommendations for professional societies to consider include: unifying implementation science activities through a single organizational structure, linking front-line clinicians with implementation scientists, seeking collaborations to prioritize and conduct implementation science studies, supporting implementation science projects through funding opportunities, working with research funding bodies to set the research agenda in the field, collaborating with external bodies responsible for health care delivery, disseminating results of implementation science through scientific journals and conferences, and teaching the next generation about implementation science through courses and other media.Implementation science plays an increasingly important role in health care. Through support of implementation science, the ATS and other professional medical societies can work with other stakeholders to lead this effort.
Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids — Anchorage, Alaska, 2015–2016
Authors: Yuri P. Springer, Roy Gerona, Erich Scheunemann, Sarah L. Shafer, Thomas Lin, Samuel D. Banister, Michael P. Cooper, Louisa J. Castrodale, Michael Levy, Jay C. Butler, Joseph B. McLaughlin
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In July 2015, personnel in the Alaska Division of Public Health's Section of Epidemiology became aware of an increase in the number of patients being treated in Anchorage hospital emergency departments for adverse reactions associated with use of synthetic cannabinoids (SCs). SCs are a chemically diverse class of designer drugs that bind to the same cannabinoid receptors as tetrahydrocannabinol, the main psychoactive component of cannabis. A public health investigation was initiated to describe clinical outcomes, characterize the outbreak, and identify SC chemicals circulating in Anchorage. During July 15, 2015-March 15, 2016, a total of 1,351 ambulance transports to Anchorage emergency departments for adverse SC reactions were identified. A review of charts obtained from two Anchorage hospitals determined that among 167 emergency department visits for adverse SC reactions during July 15-September 30, 2015, 11 (6.6%) involved a patient who required endotracheal intubation, 17 (10.2%) involved a patient who was admitted to the intensive care unit, and 66 (39.5%) involved a patient classified as being homeless. Testing of 25 product and paraphernalia samples collected from patients at one hospital identified 11 different SC chemicals. Educational outreach campaigns focused on the considerable health risks of using SCs need to complement judicial and law enforcement actions to reduce SC use.
PTH-122 Multidisciplinary team approach is accurate in diagnosing benign liver lesions: Abstract PTH-122 Table 1
Authors: A Sinha, A Dhanda, P Collins
Journal: Gut (2015)

<h3>Introduction</h3> Focal liver lesions are common incidental findings and the differential diagnosis includes benign and malignant conditions. Cross sectional imaging and review in multidisciplinary team (MDT) is usually sufficient to obtain accurate diagnosis and biopsy/resection is reserved for indeterminate cases. We describe the nature of benign focal liver lesions discussed at a regional HPB MDT and determine the frequency of missed or inaccurate diagnoses. <h3>Method</h3> Our regional MDT serves a population of 2 million. We obtained records of all liver lesions referred for discussion between 2007 and 2013. Cases where the initial diagnosis was that of a benign liver lesion were selected and patient demographics, mode of presentation, background liver disease, diagnosis, management and follow up data were collected. We also analysed the cases where the initial diagnosis was subsequently changed to either a new benign or a malignant diagnosis. <h3>Results</h3> 245 cases were identified (males 32.2%; median age 54; range 16–88). 173 lesions were discovered as incidental findings, 54 patients were symptomatic and 16 cases had abnormal liver function tests leading to their presentation. 2 cases were diagnosed as a part of routine HCC surveillance. 128 patients had background liver disease (18 alcohol related and 110 non-alcohol related liver diseases). Haemagioma and Focal nodular hyperplasia (FNH) were the most common diagnoses (Table 1). 10 patients had two or more diagnoses. The overall 1 year survival for all cases was 99.6%. 236 cases (96.3%) were given a final benign diagnosis. Only 18 cases were identified where there was a change in initial diagnosis. The average number of months before the new diagnosis was made was 9.5 months (median 9 months, range 2–30 months). A new diagnosis of malignant lesion was made in 9 cases (3. 7%) which lead to a change in their management. Of these patients, 4 were deceased at the time of writing giving a median survival of 27.7 months (range 4–48 months) since first presentation to our MDT and 20.4 months (range 2–38 months)since revision of their original benign diagnosis. Univariate analysis finds that age is higher (63 v 54; p = 0.008) and presence of background liver disease more common (66.7% v 15.4%; p = 0.001) in those that subsequently had a malignant diagnosis. Multivariate analysis confirmed that both age and background liver diseases are independent predictors of a subsequent malignant diagnosis. <h3>Conclusion</h3> This study highlights the value of an MDT approach in the accuracy of diagnosing benign liver lesions (96.3%) and advocates this practice to continue. Additional care should be taken to exclude malignancy in older patients with background chronic liver disease. <h3>Disclosure of interest</h3> None Declared.
TCT-111 Impact of Concomitant Mitral Regurgitation Following Transcatheter Aortic Valve Replacement: Insights from the US TVT National Registry
Authors: Kreton Mavromatis, Vasilis Babaliaros, Amanda Stebbins, Sreekanth Vemulapalli, Chandan Devireddy, Robert Guyton, Peter C. Block, Bradley G. Leshnower, Eric Sarin, James Stewart, Stamatios Lerakis, John S. Rumsfeld, Vinod Thourani
Journal: Journal of the American College of Cardiology (2015)
Adoptive Transfer and Consequential Selective Reconstitution of Streptamer-Selected Cytomegalovirus-Specific CD8+ T Cells Leads to Enduring Virus Clearance in Patients after Allogeneic Stem Cell Transplantation
Authors: Anita Schmitt, Torsten Tonn, Dirk Busch, Götz Grigoleit, Hermann Einsele, Marcus Odendahl, Lothar Germeroth, Mark Ringhoffer, Simone Ringhoffer, Markus Wiesneth, Detlef Michel, Thomas Mertens, Markus Rojewski, Martin Marx, Stephanie Harsdorf, Hartmut Döhner, Erhard Seifried, Donald Bunjes, Michael Schmitt
Journal: Blood (2008)
Molecular Signature of Distinct CD34+ Hematopoietic Stem and Progenitor Cell Subsets of Patients with CML in Chronic Phase.
Authors: Ingmar Bruns, Akos G. Czibere, Johannes C. Fischer, Ulrich Steidl, Sabrina Pechtel, Annemarie Koch, Daniela Brünnert, Sebastian Büst, Ron-Patrick Cadeddu, Ralf Kronenwett, Rainer Haas
Journal: Blood (2007)
Selection of Human Anti-CD22 scFvs from an Acute Lymphocytic Leukemia Related scFv Library with Ribosome Display.
Authors: Achim Rothe, Ralf J. Hosse, Anne Nathanielsz, Frank Oberhaeuser, Elke Pogge von Strandmann, Andreas Engert, Peter J. Hudson, Barbara E. Power
Journal: Blood (2006)
Clinicopathological differences between EBV-positive and EBV-negative diffuse large B-cell lymphoma.
Authors: B. E. Beltran, D. Morales, A. Capellino, R. Miranda, J. Castillo
Journal: Journal of Clinical Oncology (2010)

8083 Background: Epstein Barr virus-positive diffuse large B-cell lymphoma (EBV-positive DLBCL) of the elderly is a new entity considered in the new WHO classification of lymphoid malignancies. EBV-positive DLBCL is a very aggressive entity with a short survival. Few data comparing the clinicopathological features between EBV-positive and EBV-negative DLBCL are available. Our study attempts to compare these characteristics and also identify prognostic factors. Methods: Between January 2002 and December 2009, 102 patients diagnosed with DLBCL were included in the analysis; 21 cases were EBV-positive and 81 cases were EBV-negative. Clinical data were reviewed retrospectively and patient's biopsies were analyzed for the immunohistochemical expression of bcl-6, CD10, CD30 and MUM-1. Samples from patients were also analyzed for the presence of EBV-encoded RNA (EBER). Descriptive statistics were used to assess categorical and continuous variables. Survival curves for OS were estimated using the Kaplan-Meier method and compared using the log-rank test. For the multivariate analysis, the Cox proportional-hazard regression test was used. Results: Mean age for EBV-positive and EBV-negative patients was 73 and 65years, respectively (p=0.043). Sex, LDH levels, performance status, clinical stage, response to initial treatment and extranodal involvement were not significantly different between groups. The EBV status demonstrated a substantially poorer overall survival 3 months (95% CI, 0.0–2.6 months) and 15.5 months (1.0–43.0 months) in EBV-positive and EBV-negative, respectively (p=0.022). At the multivariate level, EBV status was an independent factor compared with the International Prognostic Index (IPI) score (p=0.001) with a 2.4-fold (95% CI, 1.2–4.8) risk for death for EBV-positive cases. In the EBV-positive group, a non-germinal center profile, the Oyama score and the IPI score were associated with survival. In the multivariate analysis only IPI score was significant (p=0.0045). Conclusions: EBV- positive DLBCL correlated with advanced age and a poor survival in comparison with EBV-negative DLBCL. The IPI score was a better prognostic tool than the Oyama score in EBV-positive patients. No significant financial relationships to disclose.
Incidence, Outcome and Risk Factors of Pseudotumor Cerebri after All- Trans Retinoic Acid and Anthracycline-Based Chemotherapy in Patients with Acute Promyelocytic Leukemia
Authors: Pau Montesinos, Edo Vellenga, Aleksandra Holowiecka, Chelo Rayon, Gustavo Milone, Javier de la Serna, Angel Leon, Juan Bergua, Concha Rivas, Jose Gonzalez, Jordi Esteve, Miguel A. Sanz
Journal: Blood (2008)